Clinical Trial Update: A Dose Response Study of E6011 in Participants With Rheumatoid Arthritis Inadequately Responding to Methotrexate [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for E6011 in rheumatoid arthritis patients inadequately responding to methotrexate has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• E6011

Snippet

Sponsor: Eisai Co., Ltd. | Conditions: Rheumatoid Arthritis | Phase 2 | Status: COMPLETED | Results posted: 2021-06-21